The clinical trial investigates a new treatment for Cushing’s disease, a rare condition where the body produces too much of a hormone called cortisol. The excess cortisol is caused by high levels of another hormone called adrenocorticotropic hormone (ACTH) that comes from the pituitary gland in the brain. This condition can lead to various health problems if left untreated.
The study will test a new medicine called Lu AG13909, which is a humanized antibody that targets ACTH. The medication will be given in two different ways: as an injection under the skin (subcutaneous use) and through a vein (intravenous use). The study aims to understand how well the medicine works in controlling cortisol levels and how safe it is for patients.
During the trial, participants will receive the study medication for up to 910 days. The researchers will monitor the amount of cortisol in participants’ urine and how the medicine moves through the body. They will also track any side effects that may occur during the treatment period. This is a Phase II trial, which means the medication has already been tested for basic safety in humans, and now researchers are studying how well it works for treating Cushing’s disease.
France 
Hungary 
Italy 
Poland 
Romania 
Spain 
